Healthcare provider profile · identity verified

Brent Boggess, MD

Family Practice · SAGINAW, MI · NPI 1407852064

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	716	225
Amlodipine Besylate	Amlodipine Besylate	683	212
Lisinopril	Lisinopril	611	193
Hydrochlorothiazide	Hydrochlorothiazide	399	127
Simvastatin	Simvastatin	336	103
Levothyroxine Sodium	Levothyroxine Sodium	313	92
Omeprazole	Omeprazole	310	99
Metoprolol Succinate	Metoprolol Succinate	303	95
Metformin Hcl	Metformin Hcl	272	84
Losartan Potassium	Losartan Potassium	244	75
Metoprolol Tartrate	Metoprolol Tartrate	200	61
Allopurinol	Allopurinol	196	56
Tamsulosin Hcl	Tamsulosin Hcl	185	58
Eliquis	Apixaban	180	47
Ezetimibe	Ezetimibe	143	38
Furosemide	Furosemide	137	52
Sertraline Hcl	Sertraline Hcl	136	41
Potassium Chloride	Potassium Chloride	125	39
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	124	40
Glimepiride	Glimepiride	111	34
Famotidine	Famotidine	108	35
Gabapentin	Gabapentin	106	42
Doxazosin Mesylate	Doxazosin Mesylate	103	28
Albuterol Sulfate Hfa	Albuterol Sulfate	102	33
Pantoprazole Sodium	Pantoprazole Sodium	93	28
Prednisone	Prednisone	93	76
Fenofibrate	Fenofibrate	88	24
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	81	29
Carvedilol	Carvedilol	74	24
Fluticasone Propionate	Fluticasone Propionate	73	29
Atenolol	Atenolol	69	24
Clopidogrel	Clopidogrel Bisulfate	69	24
Mirtazapine	Mirtazapine	69	20
Warfarin Sodium	Warfarin Sodium	66	17
Isosorbide Mononitrate Er	Isosorbide Mononitrate	64	19
Rosuvastatin Calcium	Rosuvastatin Calcium	63	22
Jardiance	Empagliflozin	61	17
Triamcinolone Acetonide	Triamcinolone Acetonide	55	30
Montelukast Sodium	Montelukast Sodium	52	21
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	51	15
Fluoxetine Hcl	Fluoxetine Hcl	49	12
Pioglitazone Hcl	Pioglitazone Hcl	48	15
Alendronate Sodium	Alendronate Sodium	45	14
Fenofibrate	Fenofibrate Nanocrystallized	44	12
Meloxicam	Meloxicam	44	20
Azithromycin	Azithromycin	42	38
Pravastatin Sodium	Pravastatin Sodium	42	suppressed
Lorazepam	Lorazepam	41	20
Oxybutynin Chloride Er	Oxybutynin Chloride	41	14
Escitalopram Oxalate	Escitalopram Oxalate	37	12
Enalapril Maleate	Enalapril Maleate	36	12
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	36	12
Ropinirole Hcl	Ropinirole Hcl	35	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	34	suppressed
Citalopram Hbr	Citalopram Hydrobromide	30	suppressed
Glipizide	Glipizide	30	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	30	22
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	30	suppressed
Glipizide Er	Glipizide	29	12
Buspirone Hcl	Buspirone Hcl	27	suppressed
Alprazolam	Alprazolam	26	suppressed
Clobetasol Propionate	Clobetasol Propionate	26	12
Paroxetine Hcl	Paroxetine Hcl	26	suppressed
Duloxetine Hcl	Duloxetine Hcl	25	suppressed
Januvia	Sitagliptin Phosphate	25	suppressed
Ramipril	Ramipril	23	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	22	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	22	suppressed
Cephalexin	Cephalexin	21	18
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	21	14
Ozempic	Semaglutide	21	suppressed
Farxiga	Dapagliflozin Propanediol	20	suppressed
Lovastatin	Lovastatin	20	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	19	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	19	15
Aripiprazole	Aripiprazole	18	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	18	13
Gemfibrozil	Gemfibrozil	18	suppressed
Nitroglycerin	Nitroglycerin	18	12
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	17	suppressed
Donepezil Hcl	Donepezil Hcl	17	suppressed
Meclizine Hcl	Meclizine Hcl	17	suppressed
Niacin Er	Niacin	17	suppressed
Amiodarone Hcl	Amiodarone Hcl	16	suppressed
Diltiazem 24hr Er	Diltiazem Hcl	16	suppressed
Finasteride	Finasteride	16	suppressed
Levetiracetam	Levetiracetam	16	suppressed
Pregabalin	Pregabalin	16	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	16	suppressed
Valsartan	Valsartan	16	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	15	suppressed
Bumetanide	Bumetanide	15	suppressed
Megestrol Acetate	Megestrol Acetate	15	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	15	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	14	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	14	suppressed
Ibuprofen	Ibuprofen	14	suppressed
Primidone	Primidone	14	suppressed
Tresiba Flextouch U-100	Insulin Degludec	14	suppressed
Hydralazine Hcl	Hydralazine Hcl	13	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	13	suppressed
Levemir Flexpen	Insulin Detemir	13	suppressed
Premarin	Estrogens, Conjugated	13	suppressed
Propranolol Hcl	Propranolol Hcl	13	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	13	suppressed
Ventolin Hfa	Albuterol Sulfate	13	suppressed
Clonidine Hcl	Clonidine Hcl	12	suppressed
Linzess	Linaclotide	12	suppressed
Acyclovir	Acyclovir	11	suppressed
Clonazepam	Clonazepam	11	suppressed
Dutasteride	Dutasteride	11	suppressed
Fenofibrate	Fenofibrate,micronized	11	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	11	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	11	suppressed
Symbicort	Budesonide/Formoterol Fumarate	11	suppressed
Terazosin Hcl	Terazosin Hcl	11	suppressed
Verapamil Er	Verapamil Hcl	11	suppressed
Victoza 3-Pak	Liraglutide	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error